EC debuts HERA Incubator to anticipate coronavirus variants

18 February 2021
european_commission_large

To prepare Europe for an increased threat of coronavirus variants, the President of the European Commission, Ursula von der Leyen, has announced the start of European bio-defense preparedness plan called “HERA Incubator.”

The Health Emergency Preparedness and Response Authority (HERA) Incubator will bring together science, industry and public authorities, and leverage all available resources to enable Europe to respond to this challenge.

“The aim is to use our combined strength to get ahead of the curve for the next phase of this virus”, Ms von der Leyen said, explaining this applies to all phases - from the early detection of new variants, to rapid mass production that is necessary if there are adapted second-level or second-generation vaccines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical